Use and outcomes of cerebral embolic protection for transcatheter aortic valve replacement: A US nationwide study.

ABSTRACT:

Background

Outcomes data on the use of cerebral embolic protection devices (CPDs) with transcatheter aortic valve replacement (TAVR) remain limited. Previous randomized trials were underpowered for primary outcomes of stroke prevention and mortality.

Methods

The National Inpatient Sample and Nationwide Readmissions Database were queried from 2017 to 2018 to study utilization and inpatient mortality, neurological complications (ischemic stroke, hemorrhagic stroke, and transient ischemic attack), procedural complications, resource utilization, and 30-day readmissions with and without use of CPD. A 1:3 ratio propensity score matched model was created.

Results

Among 108,315 weighted encounters, CPD was used in 4380 patients (4.0%). Adjusted mortality was lower in patients

SUBMITTER: Khan MZ 

PROVIDER: S-EPMC8578314 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature